This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-25 and is reviewed periodically as new material appears.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
To determine causes of diseases, medical experts used the most common and widely accepted assumptions or symptoms of their times, a general principle of approach that persists in modern medicine. Modern medicine was particularly advanced by further developments of the microscope to analyze tissues, to which Rudolf Virchow gave a significant contribution, leading to a slew of research developments. By the late 1920s to early 1930s pathology was deemed a medical specialty. Combined with developments in the understanding of general physiology, by the beginning of the 20th century, the study of pathology had begun to split into a number of distinct fields, resulting in the development of a large number of modern specialties within pathology and related disciplines of diagnostic medicine.
==== Smalley source ==== A laser vaporization cluster source produces ions using a combination of laser desorption ionization and supersonic expansion. The Smalley source (or Smalley cluster source) was developed by Richard Smalley at Rice University in the 1980s and was central to the discovery of fullerenes in 1985.
=== Global adoption === The gradual global adoption of refrigerators marks a transformative era in food preservation and domestic convenience. Since the refrigerators introduction in the 20th century, refrigerators have transitioned from being luxurious items to everyday commodities which have altered the understandings of food storage practices. Refrigerators have significantly impacted various aspects of many individual's daily lives by providing food safety to people around the world spanning across a wide variety of cultural and socioeconomic backgrounds. The global adoption of refrigerators has also changed how societies handle their food supply. The introduction of the refrigerator in different societies has resulted in the monetization and industrialized mass food production systems which are commonly linked to increased food waste, animal wastes, and dangerous chemical wastes being traced back into different ecosystems. In addition, refrigerators have also provided an easier way to access food for many individuals around the world, with many options that commercialization has promoted leaning towards low-nutrient dense foods. After consumer refrigerators became financially viable for production and sale on a large scale, their prevalence around the globe expanded greatly. In the United States, an estimated 99.5% of households have a refrigerator. Refrigerator ownership is more common in developed Western countries, but has stayed relatively low in Eastern and developing countries despite its growing popularity.
==== F ==== Dried fig – is used in food products such as fig rolls. Traditional dried fruit – are types of dried fruits that are either sun-dried, such as raisins and dried figs, or dehydrated in wind tunnels and other dryers, such as dried plums (prunes), apricots, and peaches.
UV degradation is one form of polymer degradation that affects plastics exposed to sunlight. The problem appears as discoloration or fading, cracking, loss of strength or disintegration. The effects of attack increase with exposure time and sunlight intensity. The addition of UV absorbers inhibits the effect.
Sources: en.wikipedia.org
== Oil == Peppermint oil has a high concentration of natural pesticides, mainly pulegone found mostly in "M. arvensis var. piperascens" (Mentha canadensis), and to a lesser extent in Mentha × piperita and menthone. It is known to repel some pest insects, including mosquitos. Main constituents of the essential oil from Mentha × piperita are menthol (41%) and menthone (23%). The oil is used in flavours and fragrances. Its aroma defines "peppermint".
Although no data illustrate the direct association of YTXs and toxicity in humans, issues with regards to the potential health risks of YTXs still stand due to the significant animal toxicity observed, and like other algal toxins present within shellfish, YTKs are not destroyed by heating or freezing. As a result, several countries, including New Zealand, Japan, and those in Europe, regulate the levels of YTXs in shellfish. In 2002, the European Commission placed the regulatory level at 1 μg of YTXs per g (1 mg/kg) of shellfish meat intended for human consumption (Directive 20012/225/EC). Recently, it was shown that yessotoxins can trigger ribotoxic stress.
=== Cation-exchange resin === Formula: R−H acidic The cation exchange method removes the hardness of water but induces acidity in it, which is further removed in the next stage of treatment of water by passing this acidic water through an anion exchange process. Reaction:
cuvette A type of small container used in spectroscopy experiments, usually made of plastic, glass, or quartz and designed to hold a sample (typically a liquid) for measurement inside a spectrometer. Cuvettes should be as clean and transparent as possible to minimize interference with the beams of light on which spectroscopic techniques rely.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.